However, it's important to note that tirzepatide is not FDA-approved for the treatment of MASLD or MASH, and any such use would be considered off-label
Ketogenic nutritional therapy (KeNuT)a multi-step dietary model with meal replacements for the management of obesity and its related metabolic disorders: a consensus statement from the working group of the club of the Italian society of endocrinology (SIE)diet therapies in endocrinology and metabolism
Tirzepatide is popular because it appears to produce greater weight loss by stimulating two satiety hormone receptors instead of one
But if a 50-mg daily dose is prescribed (which will likely be an off-label dosage), people may actually lose more weight on the Wegovy pill vs
On the population level, obesity is associated with a host of major ills, and Americans have long been desperate to lose weight
Response: We acknowledge commenter's concern about outdated data and collection periods that do not always align across measures